ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2849

Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations

David Fernandez1, Mikhail Olferiev1, Leila Khalili1, Kyriakos A. Kirou2 and Mary K. Crow1, 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus, mixed connective tissue disease (MCTD) and ribonucleoprotein (RNP)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against nucleic acids and a variety of self-antigens. Recent work indicates that immune complexes containing anti-U1 Ribonucleoprotein (anti-RNP) can drive formation of neutrophil extracellular traps, which in turn can drive interferon-α production by plasmacytoid dendritic cells. (1) We hypothesized that patients with anti-RNP may be more likely to exhibit a specific pattern of SLE disease features, potentially implicating neutrophils in the pathogenesis of those features.

Methods: Clinical data from 160 patients enrolled in the FLARE cohort of SLE patients at Hospital for Special Surgery were reviewed in a retrospective fashion. All patients had been tested for anti-Ro, anti-La, anti-Sm, and anti-RNP at the time of enrollment, and patients were classified as being positive or negative for anti-RNP, whether alone or in combination with other autoantibodies. Each patient’s record was reviewed and the presence or absence of a total of 90 disease manifestations and laboratory features at any point in their history were recorded. Differences in the incidence of various phenotypes in different groups were compared between groups using Chi square tests. P values were not adjusted for multiple comparisons in this exploratory analysis.

Results: We identified 83 patients who were positive for anti-RNP antibodies (anti-RNP+), and 77 patients who were anti-RNP negative (anti-RNP(-)). We identified several disease features that differed between anti-RNP+ and anti-RNP(-) patients (Table 1). Specifically, some features classically associated with mixed connective tissue disease were seen more commonly in the RNP+ patients, such as sclerodactyly and myositis. Additionally, a history of vasculitis or elevated serum globulin (>3.5g/dL) were observed more commonly in the anti-RNP+ group. In contrast, anti-RNP(-) patients were more likely to have had a history of immune thrombocytopenic purpura or thrombocytopenia. While there was no significant difference in the prevalence of nephritis overall between the groups, membranous (class V) nephritis was more common in the anti-RNP+ patients, while proliferative (class III/IV) nephritis was more common in the anti-RNP(-) patients.

Conclusion: We demonstrated several disease manifestations which were more likely to be occur in anti-RNP+ individuals, such as vasculitis and membranous nephritis, as well as some which were more likely in anti-RNP(-) patients, such as proliferative nephritis and thrombocytopenia. The role of neutrophil activation and anti-RNP antibodies in these specific disease manifestations merits further investigation. 1.       Garcia-Romo, G.S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).


Disclosure: D. Fernandez, None; M. Olferiev, None; L. Khalili, None; K. A. Kirou, None; M. K. Crow, Medimmune, 5.

To cite this abstract in AMA style:

Fernandez D, Olferiev M, Khalili L, Kirou KA, Crow MK. Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-patients-with-antibodies-against-u1-ribonucleoprotein-exhibit-a-specific-pattern-of-disease-manifestations/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-patients-with-antibodies-against-u1-ribonucleoprotein-exhibit-a-specific-pattern-of-disease-manifestations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology